
FDA Approves Sebetralstat for Hereditary Angioedema
Sebetralstat (Ekterly; KalVista Pharmaceuticals) is now approved by the FDA for on-demand treatment of hereditary angioedema, with supportive data from the phase 3, double-blind, 3-way crossover KONFIDENT trial (NCT05259917) and its open-label extension …